Concepedia

Evaluating the risk of infections under interleukin 23 and interleukin 17 inhibitors relative to tumour necrosis factor inhibitors – A population‐based study

Khalaf Kridin, Henner Zirpel, Noor Mruwat, Ralf J. Ludwig, Diamant Thaçi

Journal of the European Academy of Dermatology and Venereology · 2023 · 26 citations · 13 references

DOIFull text

Open access

Abstract

Compared with TNFi, IL-23i and IL-17i are associated with decreased risk of several infectious diseases. These agents might be preferred in patients with susceptibility to infections.

References

13

A comparison of 12 algorithms for matching on the propensity score

Peter C. Austin · Statistics in Medicine · 2013 · 1K citations · Full text

, , +19

Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents

Anja Strangfeld · JAMA · 2009 · 538 citations

Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis

Robert E. Kalb, David Fiorentino, Mark Lebwohl et al. · JAMA Dermatology · 2015 · 364 citations

Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial

Kristian Reich, April W. Armstrong, Richard G. Langley et al. · The Lancet · 2019 · 362 citations

, , +6

Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?

Anja Strangfeld, Maria Eveslage, Matthias Schneider et al. · Annals of the Rheumatic Diseases · 2011 · 358 citations · Full text